C8orf4 (inhibited by trastuzumab) is highly expressed in several tumors and is implicated in tumorigenesis; C8orf4 augments Wnt/β-catenin signaling in cancer cells, suggesting that it may be involved in the regulation of self-renewal [68]. Here, TCIM is linked to cancer.